There is one clinical trial.
The hemostatic abnormalities in COVID-19 are related with disease progression, severity and mortality. The Objective of our study is to evaluate the role of hematological parameters in determination of COVID-19 disease severity.
Description: disease severity was assessed on basis of hematological parameters.Measure: complete blood count- Hemoglobin. White blood count, platelet count, Neutrophil to lymphocyte ratio Time: 3 months
Description: improvement in PT, APTT and D-dimer levels were assessedMeasure: PT, APTT and D-dimer Time: 3 months
Description: improvement in LDH and were assessedMeasure: LDH, serum ferritin level Time: 3 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports